Personalis Inc. Common Stock (PSNL)
Stock · NASDAQ · Health Care
$15.66as of 10/16/2026
Price chart
Active signals
PSNL Signal Track Record
How signals performed across all stocks →What PSNL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -6.0% | 43% | October 6, 2026 |
| Bollinger Band Breakout | 26 | -5.2% | 46% | August 19, 2026 |
| Bollinger Band Breakdown | 17 | -1.9% | 47% | October 6, 2026 |
| 200-Day Moving Average Touch | 8 | -14.9% | 38% | August 29, 2025 |
| Any 20-session window (baseline) | -3.0% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PSNL
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 259
- Website
- www.personalis.com/
Fundamentals
- 1-day range
- $15.52$16
- Market cap
- $1.39B
- P/E (trailing)
- —
- P/E (forward)
- -16.56
- EPS (trailing)
- $-1.09
- Dividend yield
- —
- Beta
- 2.37
- Avg. volume
- 3.17M
How Personalis Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Personalis Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PSNLPersonalis Inc. Common Stock$15.65▼ 1.76%Market cap $1.39BP/E —$4.96$18.89
- TRUPTrupanion Inc. Common Stock$28.12▲ 0.93%Market cap $1.23BP/E 53.48$21.16$46.98
- FRNMFreenome Inc. Common stock$11.75▼ 4.35%Market cap $1.17BP/E —$9.97$17.5
- FTREFortrea Holdings Inc. Common Stock$22.49▼ 1.12%Market cap $1.68BP/E —$8.55$23.51
- LMRILumexa Imaging Holdings Inc. Common Stock$10.78▲ 0.00%Market cap $1.10BP/E —$6.45$19.45
- CSTLCastle Biosciences Inc. Common Stock$31.96▼ 5.44%Market cap $930.84MP/E —$17.72$44.28
- FLGTFulgent Genetics Inc. Common Stock$19.81▼ 7.17%Market cap $510.41MP/E —$13.46$31.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PSNL Personalis Inc. Common Stock | $1.39B | — | $15.65 | ▼ 1.76% | $4.96$18.89 |
| TRUP Trupanion Inc. Common Stock | $1.23B | 53.48 | $28.12 | ▲ 0.93% | $21.16$46.98 |
| FRNM Freenome Inc. Common stock | $1.17B | — | $11.75 | ▼ 4.35% | $9.97$17.5 |
| FTRE Fortrea Holdings Inc. Common Stock | $1.68B | — | $22.49 | ▼ 1.12% | $8.55$23.51 |
| LMRI Lumexa Imaging Holdings Inc. Common Stock | $1.10B | — | $10.78 | ▲ 0.00% | $6.45$19.45 |
| CSTL Castle Biosciences Inc. Common Stock | $930.84M | — | $31.96 | ▼ 5.44% | $17.72$44.28 |
| FLGT Fulgent Genetics Inc. Common Stock | $510.41M | — | $19.81 | ▼ 7.17% | $13.46$31.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructurebenzinga · 10/7/2026
- Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine InfrastructureBenzinga · 10/7/2026
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha · 10/7/2026
- This Gentex Analyst Turns Bearish; Here Are Top 5 Downgrades For TuesdayBenzinga · 10/6/2026
- BTIG Downgrades Personalis to NeutralBenzinga · 10/6/2026
- Personalis: The Wrong Side Of The MergerSeekingAlpha · 9/30/2026
- Tempus AI Sees Pricing, Data Growth Fueling Long-Term ExpansionYahoo · 9/22/2026
- Tempus AI Stock Surges as Revenue Optimism Boosts Winning StreakYahoo · 9/17/2026
Insider Activity
Insider Actions →- Moore Stephen Michael · September 18, 2026 · Sale2.1K @ $16.22
- Chen Richard · September 18, 2026 · Sale4.0K @ $16.22
- Hall Christopher M · September 18, 2026 · Sale7.5K @ $16.22
- Tachibana Aaron · September 18, 2026 · Sale2.9K @ $16.22
- Chen Richard · July 15, 2026 · Option Exercise100.0K @ $2.44
- Chen Richard · July 15, 2026 · Sale100.0K @ $15.15
- Hall Christopher M · July 9, 2026 · Option Exercise100.0K @ $1.61
- Hall Christopher M · July 9, 2026 · Option Exercise33.3K
- Hall Christopher M · July 9, 2026 · Option Exercise66.7K
- Hall Christopher M · July 9, 2026 · Sale100.0K @ $15.08
- Hall Christopher M · June 26, 2026 · Option Exercise100.0K @ $1.61
- Hall Christopher M · June 26, 2026 · Sale100.0K @ $13.15
- Tachibana Aaron · June 26, 2026 · Sale51.3K @ $13.18
- Tachibana Aaron · June 26, 2026 · Option Exercise22.4K @ $5.32
- Tachibana Aaron · June 26, 2026 · Option Exercise28.8K @ $9.16
Institutional Ownership
March 31, 2026
- Total shares held
- 83.20M
- Total value held
- $488.00M
- Institutional holders
- 136
- Unknown14.04M
- Unknown8.16M
- Unknown7.94M
- Unknown7.59M
- Unknown5.39M
- Unknown4.76M
- Unknown3.49M
- Unknown3.00M
- Unknown2.90M
- Unknown2.87M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Competitors Tempus and Natera draw market attention
Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.
Competitors Tempus and Natera draw market attention. Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.